Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models

Citation
B. Gametchu et al., Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models, STEROIDS, 64(1-2), 1999, pp. 107-119
Citations number
47
Categorie Soggetti
Biochemistry & Biophysics
Journal title
STEROIDS
ISSN journal
0039128X → ACNP
Volume
64
Issue
1-2
Year of publication
1999
Pages
107 - 119
Database
ISI
SICI code
0039-128X(199901/02)64:1-2<107:PMGRIR>2.0.ZU;2-8
Abstract
The presence of the glucocorticoid (GC) receptor is required for GC-evoked apoptosis. However, the explicit mechanism of involvement of this receptor continues to be debated. Employing the murine (S-49) and human (CCRF-CEM) l ymphoid cell lines, we demonstrated that this response requires a specializ ed form of the glucocorticoid receptor (GR) that resides in the plasma memb rane (mGR). Our studies of mGR have been done in our stable mGR-enriched (b y sequential cell separation-immunopanning, fluorescent cell sorting, soft agar cloning) S-49 and CCRF-CEM cells. Direct and indirect immunofluorescen t studies of live intact cells showed GR-specific periplasma membrane stain ing. Immunoanalysis by Flow cytometry demonstrated abundant mGR in mGR(++) cells, but only barely detectable mGR in mGR(--) cells. Western blot and au toradiographic analyses of immunoprecipitated membrane extracts from these cells show they contain Immunoreactive and competitively labeled high M-r, receptor ranging from 94 to 150 kDa. Using mGR(++) CCRF-CEM cells and three synchronization procedures (double thymidine, thymidine/colcemid, and colc emid blocks), we have investigated the influence of cell cycle on regulatio n and function of mGR. Both mGR expression and GC-mediated lymphocytolysis appear highest at late S-G2/M. Analysis of mGR in lymphocytes of several le ukemic patients indicated differences in the levels of receptor expression. These findings might provide diagnostic clues about patients' differential response to steroid therapy and potential therapeutic avenues for effectiv e treatment of hormone-responsive leukemic patients. (C) 1999 Elsevier Scie nce Inc. All rights reserved.